1,098
Views
0
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results

ORCID Icon, , , , , & ORCID Icon show all
Pages 230-239 | Received 23 Nov 2023, Accepted 11 Jan 2024, Published online: 13 Feb 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.